Quote this publication Share Print


Opinions on drugs - Posted on Apr 26 2012

Reason for request

Inclusion on the list of medicines reimbursed by National Health Insurance and approved for hospital use.


Actual benefit


The actual benefit of RASILEZ HCT products is substantial.

Improvement in actual benefit

V (absence)

RASILEZ HCT 150 mg/12.5 mg, 150 mg/25 mg, 300 mg/12.5 mg and 300 mg/25 mg fixed-dose combinations of aliskiren 150 or 300 mg and hydrochlorothiazide 12.5 or 25 mg provide no improvement in actual benefit (IAB V) in comparison with concurrent use of the two active substances taken separately.

Contact Us

Évaluation des médicaments

See also

All our publication